Deregulated expression of the per2 gene in human colorectal carcinoma

Molecular Medicine Reports

Volumn 1, Issue 4, 2008, Pages 599-603

  Zeman, Michal ^a   Vician, Marián ^a   Monosíková, Jana ^a   Reis, Richard ^a   Herichová, Iveta ^a  

^a Physics and Informatics   (Slovakia)

Author keywords

Cancer; Circadian; Clock genes; K ras; mrpl19

Indexed keywords

MESSENGER RNA; PER2 PROTEIN; TRANSCRIPTION FACTOR CLOCK;

ADULT; AGED; ARTICLE; ASCENDING COLON; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CARCINOGENESIS; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CODON; COLON; COLON RESECTION; COLORECTAL CARCINOMA; COLORECTAL SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DESCENDING COLON; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HOSPITAL POLICY; HUMAN; HUMAN TISSUE; LIGHT EXPOSURE; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; PROTEIN ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECTUM; TUMOR LOCALIZATION;

EID: 67650819280     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.1.4.599     Document Type: Article

References (39)

1. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Fuchs CS and Colditz GA: Night-shift work and risk of colorectal cancer in the nurses' health study. J Natl Cancer Inst 95: 825-828, 2003. (Pubitemid 36798430)
2. Davis S, Mirick DK and Stevens RG: Night shift work, light at night and risk of breast cancer. J Natl Cancer Inst 93: 1557-1562, 2001. (Pubitemid 32998485)
3. Hansen J: Increased breast cancer risk among women who work predominantly at night. Epidemiology 12: 74-77, 2001. (Pubitemid 32006465)
4. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I and Colditz GA: Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst 93: 1563-1568, 2001. (Pubitemid 32998486)
5. Ko CH and Takahashi JS: Molecular components of the mammalian circadian clock. Hum Mol Genet 15: R271-R277, 2006. (Pubitemid 44446803)
6. Damiola F, Le Minh N, Preitner N, Kornmann B, Fleury-Olela F and Schibler U: Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus. Genes Dev 14: 2950-2961, 2000.
7. Hara R, Wan K, Wakamatsu H, Aida R, Moriya T, Akiyama M and Shibata S: Restricted feeding entrains liver clock without participation of the suprachiasmatic nucleus. Genes Cells 6: 269-278, 2001. (Pubitemid 32273389)
8. Stokkan KA, Yamazaki S, Tei H, Sakaki Y and Menaker M: Entrainment of the circadian clock in the liver by feeding. Science 291: 490-493, 2001. (Pubitemid 32097074)
9. Okamura H, Yamaguchi S and Yagita K: Molecular machinery of the circadian clock in mammals. Cell Tissue Res 309: 47-56, 2002. (Pubitemid 34744028)
10. Fu L, Pelicano H, Liu J, Huang P and Lee C: The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111: 41-50, 2002.
11. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F and Okamura H: Control mechanism of the circadian clock for timing of cell division in vivo. Science 302: 255-259, 2003. (Pubitemid 37248750)
12. Miller BH, McDearmon EL, Panda S, Hayes KR, Zhang J, Andrews JL, Antoch MP, Walker JR, Esser KA, Hogenesch JB and Takahashi JS: Circadian and CLOCK-controlled regulation of the mouse transcriptome and cell proliferation. Proc Natl Acad Sci USA 104: 3342-3347, 2007. (Pubitemid 46364161)
13. Iurisci I, Filipski E, Reinhardt J, Bach S, Gianella-Borradori A, Iacobelli S, Meijer L and Lévi F: Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res 66: 10720-10728, 2006. (Pubitemid 44876967)
14. Filipski E, Delaunay F, King VM, Wu MW, Claustrat B, Gréchez- Cassiau A, Guettier C, Hastings MH and Francis L: Effects of chronic jet lag on malignant growth in mice. Cancer Res 64: 7879-7885, 2004. (Pubitemid 39446921)
15. Filipski E, Innominato PF, Wu M, Li XM, Iacobelli S, Xian LJ and Lévi F: Effects of light and food schedules on liver and tumor molecular clocks in mice. J Natl Cancer Inst 97: 507-517, 2005. (Pubitemid 40590432)
16. Granda TG, Liu XH, Smaaland R, Cermakian N, Filipski E, Sassone-Corsi P and Lévi F: Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor. FASEB J 19: 304-306, 2005. (Pubitemid 40189290)
17. Gery S, Gombart AF, Yi WS, Koeffler C, Hofmann WK and Koeffler HP: Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood 106: 2827-2836, 2005. (Pubitemid 41510760)
18. Gery S, Komatsu N, Baldjyan L, Yu A, Koo D and Koeffler HP: The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell 22: 375-382, 2006.
19. Hua H, Wang Y, Wan C, Liu Y, Zhu B, Yang C, Wang X, Wang Z, Cornelissen-Guillaume G and Halberg F: Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci 97: 589-596, 2006. (Pubitemid 44056606)
20. Hua H, Wang Y, Wan C, Liu Y, Zhu B, Wang X, Wang Z and Ding JM: Inhibition of tumorigenesis by intratumoral delivery of the circadian gene mPer2 in C57BL/6 mice. Cancer Gene Ther 14: 815-818, 2007. (Pubitemid 47262754)
21. Pardini L, Kaeffer B, Trubuil A, Bourreille A and Galmiche JP: Human intestinal circadian clock: expression of clock genes in colonocytes lining the crypt. Chronobiol Int 22: 951-961, 2005. (Pubitemid 43062243)
22. Krugluger W, Brandstaetter A, Kállay E, Schueller J, Krexner E, Kriwanek S, Bonner E and Cross HS: Regulation of genes of the circadian clock in human colon cancer: reduced period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors. Cancer Res 67: 7917-7922, 2007. (Pubitemid 47281388)
23. Szabo A, Perou CM, Karaca M, Perreard L, Quackenbush JF and Bernard PS: Statistical modeling for selecting housekeeper genes. Genome Biol 5: R59, 2004.
24. Hatzaki A, Razi E, Anagnostopoulou K, Iliadis K, Kodaxis A, Papaioannou D, Labropoulos S, Vasilaki M, Kosmidis P, Saetta A, Mihalatos M and Nasioulas G: A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients. Mol Cell Probes 15: 243-247, 2001. (Pubitemid 33104992)
25. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ and Chang JG: Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 26: 1241-1246, 2005.
26. Yeh KT, Yang MY, Liu TC, Chen JC, Chan WL, Lin SF and Chang JG: Abnormal expression of period 1 (PER1) in endometrial carcinoma. J Pathol 206: 111-120, 2005. (Pubitemid 40613441)
27. Iwanaga H, Yano M, Miki H, Okada K, Azama T, Takiguchi S, Fujiwara Y, Yasuda T, Nakayama M, Kobayashi M, Oishi K, Ishida N, Nagai K and Monden M: Per2 gene expressions in the suprachiasmatic nucleus and liver differentially respond to nutrition factors in rats. JPEN J Parenter Enteral Nutr 29: 157-161, 2005. (Pubitemid 44296728)
28. Hirota T, Okano T, Kokame K, Shirotani-Ikejima H, Miyata T and Fukada Y: Glucose down-regulates Per1 and Per2 mRNA levels and induces circadian gene expression in cultured Rat-1 fibroblasts. J Biol Chem 277: 44244-44251, 2002. (Pubitemid 36157857)
29. Greco C, Alvino S, Buglioni S, Assisi D, Lapenta R, Grassi A, Stigliano V, Mottolese M and Casale V: Activation of c-MYC and c-MYB proto-oncogenes is associated with decreased apoptosis in tumor colon progression. Anticancer Res 21: 3185-3192, 2001. (Pubitemid 34224216)
30. Kakisako K, Miyahara M, Uchino S, Adachi Y and Kitano S: Prognostic significance of c-myc mRNA expression assessed by semi-quantitative RT-PCR in patients with colorectal cancer. Oncol Rep 5: 441-445, 1998. (Pubitemid 128581944)
31. Nakamura KD, Duffy PH, Lu MH, Turturro A and Hart RW: The effect of dietary restriction on myc protooncogene expression in mice: a preliminary study. Mech Ageing Dev 48: 199-205, 1989. (Pubitemid 19130668)
32. Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Canon JL, Adenis A, Lo Re G, Carvalho C, Schueller J, Anciaux N, Lentz MA, Baron B, Gorlia T, Lévi F and the European Organisation for Research and Treatment of Cancer Chronotherapy Group: Phase III trial comparing 4-day chrono-modulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 24: 3562-3569, 2006. (Pubitemid 46630527)
33. Chen-Goodspeed M and Lee CC: Tumor suppression and circadian function. J Biol Rhythms 22: 291-298, 2007.
34. Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med 10: 789-799, 2004. (Pubitemid 39070849)
35. Rodenhuis S: ras and human tumors. Semin Cancer Biol 3: 241-247, 1992.
36. Huncharek M, Muscat J and Geschwind JF: K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis 20: 1507-1510, 1999. (Pubitemid 29385437)
37. Breivik J, Meling GI, Spurkland A, Rognum TO and Gaudernack G: K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. Br J Cancer 69: 367-371, 1994. (Pubitemid 24046565)
38. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M and Slattery ML: Relationship of Ki-ras mutations in colon cancers to tumor location, stage and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 9: 1193-1197, 2000. (Pubitemid 30844068)
39. Lüchtenborg M, Weijenberg MP, Wark PA, Saritas AM, Roemen GM, van Muijen GN, De Bruïne AP, van den Brandt PA and De Goeij AF: Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study. BMC Cancer 5: 160-171, 2005.